港股收评：恒指跌0.43%险守26000点，创新药概念股重挫，基建类股普涨

Market Overview - The Hong Kong stock market indices collectively declined, ending a four-day rally, with market sentiment becoming cautious [1] - The Hang Seng Index fell by 0.43%, barely holding above the 26,000-point mark, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index dropped by 0.73% and 0.24%, respectively [1] Sector Performance - Major technology stocks generally declined, with Meituan dropping 6% to reach a new low, Baidu down 2.38%, JD.com nearly 2%, and Kuaishou down 1% [1] - Biopharmaceutical stocks faced significant losses due to reports of the Trump administration planning to restrict Chinese pharmaceuticals, with innovative drug concept stocks leading the declines. For instance, Gilead Sciences plummeted by 19.66%, while Hansoh Pharmaceutical fell nearly 9% [1] - Other sectors such as film and entertainment, steel, automotive, and domestic real estate stocks also showed weakness [1] Strong Performers - Semiconductor stocks exhibited strong gains, particularly with InnoCare Pharma rising over 9% as it collaborates with NVIDIA to enhance data center operations. SMIC and Hua Hong Semiconductor both increased by approximately 6% [1] - Supported by the prospect of Federal Reserve interest rate cuts, non-ferrous metal stocks, including copper and aluminum, performed actively [1] - Infrastructure-related stocks, including military, Apple concept, building materials, heavy machinery, and high-speed rail construction stocks, also showed active performance [1]